EP. 13 PSMA-Based Imaging and Theranostics: A Summary of Current Paradigm Shifts and a Look to the Future
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPCByHannah ClarkeJuly 31st 2026
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practiceByJoshua Lang, MD, MSJuly 31st 2026
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancerByHannah ClarkeJuly 30th 2026